Treats erectile dysfunction. ANDA 204632, held by Macleods Pharms. Vardenafil Hydrochloride.
As of Nov 16, 2026, ANDA 204632 (Vardenafil Hydrochloride), held by Macleods Pharms, was first approved by FDA on Oct 22, 2019, with 1 approved supplement and 0 published complete response letters.
Vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. V ardenafil hydrochloride tablets are a phosphodiesterase 5 (PDE5) inhibitor
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2019 | Original application | Approved | None posted |
| Vardenafil HydrochlorideEQ 2.5MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 5MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 10MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 20MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Apr 22, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 22, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters